Effectiveness and cost of integrated cognitive and balance training for balance and falls in cerebellar ataxia: a blinded two-arm parallel group RCT - Winser SJ, Chan AYY, Whitney SL, Chen CH, Pang MYC.
BACKGROUND: In patients with cerebellar ataxia (CA), dual-tasking deteriorates the performance of one or both tasks. OBJECTIVE: Evaluate the effects of 4 weeks of cognitive-coupled intensive balance training (CIBT) on dual-task cost, dynamic balanc... (Source: SafetyLit)
Source: SafetyLit - February 8, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Abnormal vestibular-evoked myogenic potentials as a risk factor for unpredicted falls in spinocerebellar ataxia: a preliminary study - Choi SY, Choi KD, Choi JH, Kim JS.
This study aimed to correlate the symptoms and signs with the findings of laboratory vestibular function tests in patients with spinocerebellar ataxia (SCA). METHOD: We retrospectively recruited 26 patients with SCA (9 men, median age: 5... (Source: SafetyLit)
Source: SafetyLit - January 30, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
Funding supports ongoing Phase 1/2a clinical trial evaluating VO659 in patients with spinocerebellar ataxia type 3 and type 1 and Huntington's disease Financing led by Ackermans & van Haaren along with Droia Ventures, EQT Life Sciences and Kurma Partner... Biopharmaceuticals, Neurology, Venture Capital Vico Therapeutics, spinocerebellar ataxia, Huntington's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 5, 2024 Category: Pharmaceuticals Source Type: news

DR ELLIE CANNON: I'm dizzy and slur my words, but I still can't get a diagnosis
DR ELLIE CANNON: Ataxia is the name for a range of serious brain conditions affecting balance, speech and co-ordination. It can be a long process to get a diagnosis with a neurologist. (Source: the Mail online | Health)
Source: the Mail online | Health - December 3, 2023 Category: Consumer Health News Source Type: news

Biogen Skids On'Low-Quality' Beat, Profit Guidance Haircut
stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But analysts zeroed in on its strong launch for a Friedreich's ataxia drug. Biogen acquired the Friedreich's ataxia treatment, Skyclarys, along with Reata Pharmaceuticals for about $7.3 billion. Friedreich's ataxia…#biogen #reatapharmaceuticals #rbccapitalmarkets #brianabrahams #wedbush #laurachico #mizuhosecurities #salimsyed #rbc #abrahams (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2023 Category: Consumer Health News Source Type: news

ACR releases updated appropriateness criteria
The American College of Radiology (ACR) has released an update to its Appropriateness Criteria, which includes nine new and nine revised topics. The criteria in total include 233 diagnostic imaging and interventional radiology topics with more than 1,100 clinical variants covering more than 3,000 clinical scenarios. All topics include a narrative, an evidence table, and a literature search summary. The ACR said the criteria aim to assist referring physicians and other providers in making the most appropriate imaging or treatment decisions for specific clinical conditions. The following are the new topics: Imaging of In...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 28, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news

Take the lead - Vaphiades MS, Carey AR.
A 23-year-old previously healthy woman presented with headache, generalized seizures, ataxia, encephalopathy, abdominal pain, nausea and vomiting culminating in a 40- pound weight loss. A contrasted magnetic resonance imaging (MRI) scan of the brain showed... (Source: SafetyLit)
Source: SafetyLit - May 24, 2023 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Why Does He Rock His Body?
Discussion Stereotypies are “…patterned, repetitive, purposeless, involuntary movements that are also rhythmic and continual and tend to change little over time.” They occur at all times of the day, and can get worse with stress or heightened emotions including happiness. Stereotypies more often occur in children with developmental disabilities (up to 61%), sensory impairments (e.g. blindness) or social deprivation. They can be present more often in patients with autism (up to 88%). They can be seen in ~7% of normally developing children too. Their onset is before age 3 years and tend to improve over year...
Source: PediatricEducation.org - May 22, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Bottle mix-up: ethanol intoxication in an infant - Bageris MH, Hill EE, Benner C, Chassee TP.
Alcohol intoxication is a common ingestion in pediatrics with close to 10,000 reports to poison control centers annually. Hypoglycemia, neurological depression (ataxia, coma, nystagmus, etc.) and unstable vitals (hypothermia, hypotension, bradycardia, and ... (Source: SafetyLit)
Source: SafetyLit - May 12, 2023 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Novel ATR Inhibitor Shows Promise in Children With Tumors Novel ATR Inhibitor Shows Promise in Children With Tumors
The novel ataxia telangiectasia –mutated Rad3-related (ATR) inhibitor, ceralasertib, showed some promise in combination with olaparib in pediatric patients with tumors with DNA repair deficiencies.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Biologics by McKesson Named the Exclusive Pharmacy for FDA- Approved SKYCLARYS (omaveloxolone) for the Treatment of Friedreich ’s Ataxia
CARY, N.C., April 5, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Reata Pharmaceuticals as the sole specialty pharmacy provider for SKYCLARYSTM (omaveloxolone), the first and only treatment for Friedreich’s ataxia (FA). S... (Source: McKesson News)
Source: McKesson News - April 5, 2023 Category: Information Technology Source Type: news

What are Presentations of Neuroblastoma?
Discussion Abdominal pain is a very common problem with abdominal masses being somewhat less common. If one considers how frequently patients have abdominal pain due to constipation and that it often presents with a fecal mass, both of these are commonplace. Abdominal and pelvic organs are sometimes mistaken for masses also. As the abdominal and pelvic cavities are large, tumors often need to be quite large before they cause functional problems and/or can be palpated on physical examination. A review of abdominal masses can be found here. A review of recurrent abdominal pain can be found here. A review of acute abdominal p...
Source: PediatricEducation.org - March 27, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

First Treatment Approved for Rare Neurodegenerative Disorder
(MedPage Today) -- The FDA approved omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia in patients ages 16 and older, making it the first approved treatment for this rare progressive neurodegenerative disorder, the agency said Tuesday... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 1, 2023 Category: American Health Source Type: news

FDA OKs First Treatment for Friedreich's Ataxia FDA OKs First Treatment for Friedreich's Ataxia
Omaveloxolone has been approved for adults and adolescents aged 16 and older who have the ultra-rare neurodegenerative disorder Friedreich ' s ataxia.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 1, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news